The numbers come first. The average effective U.S. tariff rate now stands at 10.7%, up 0.1 percentage points in a single week, according to Bloomberg Economics calculations. That figure, modest on its face, is the product of a deliberate legal reconstruction — one that suggests the White House intends tariffs to be a permanent revenue and leverage instrument, not a negotiating bluff.
Canada in the crosshairs. The White House announced a 50% tariff on approximately $20 billion worth of Canadian imports — roughly 5% of the total goods crossing the northern border each year. The levies are set to take effect August 19 unless Ottawa addresses Washington's complaints on automobiles, dairy, and alcoholic beverages. Notably, the administration reached for Section 338 of the Tariff Act of 1930 — the Smoot-Hawley provision — a statutory tool that had never previously been used to impose tariffs. Bloomberg Economics analyst Chris Kennedy wrote in a research note this week that Section 338 'may become Trump's go-to tool for international disputes.'
Brazil takes the largest hit. Additional 25% tariffs under Section 301 of the Trade Act of 1974 entered into force against Brazilian imports, with exemptions carved out for coffee, beef, and certain ethanol shipments. Bloomberg Economics noted that Brazil now faces the largest tariff increase among major U.S. trading partners compared with end-of-2024 levels. Brasília responded with an 18.5 billion reais ($3.6 billion) credit package to support affected exporters.
Generic drugs: a two-year clock. In a social-media post, Trump gave generic-drug manufacturers two years to relocate production to the United States or face a 100% tariff beginning August 2028. Generic medications — ranging from common painkillers and antibiotics to cholesterol and cancer treatments — are manufactured primarily in India, Europe, and China. The announcement would, if implemented, restructure a global supply chain that has kept drug prices accessible for American consumers.
The bond market argument. Josh Lipsky, vice president and chair of International Economics at the Atlantic Council, told MS NOW on Friday: 'Donald Trump is committed to rebuilding the tariff wall.' In an essay published this week in The New York Times, Lipsky argued that the real obstacle to rolling back tariffs is no longer legal challenges but bond-market dependency: 'U.S. financial markets went from hating tariffs to being able to live with them and finally to needing them to help address the country's deficit,' he wrote. Senior Peterson Institute researcher Chad Bown offered a dissenting frame, telling BBC News that the administration 'continues to impose tariffs on partners and allies and is not addressing the more important challenge: China.'
Legal resistance continues. Small businesses filed two lawsuits in the U.S. Court of International Trade this week, alleging that the administration is illegally using Section 301 to replace the tariffs previously struck down by the Supreme Court. The 10% provisional levy that had been in place since that ruling expired Friday after 150 days; the new 10% and 12.5% duties — justified by a USTR investigation into forced-labor standards — effectively maintained the floor.
---
CEO Times view. The week's events settle a question markets had been asking since February: tariffs are not a negotiating chip to be cashed in before the midterms. They are, as Lipsky argues, becoming a structural revenue line — and that changes the calculus for every importer, manufacturer, and supply-chain planner operating across U.S. borders. Free-enterprise readers should note the irony: a policy born as leverage has become, in the bond market's eyes, a fiscal necessity. Capital rewards clear rules, even imperfect ones. The uncertainty is not whether tariffs persist — it is which obscure statute the administration reaches for next.
